In an analysis of a cohort that included nearly 1 million patients who had visited an ophthalmologist, patients who were taking oral fluoroquinolones had a higher risk of developing a retinal detachment, a serious eye condition, compared with nonusers, although the absolute risk was small, according to a study in the April 4 issue of JAMA.
“Fluoroquinolones are one of the most commonly prescribed classes of antibiotics. Their broad-spectrum antibacterial coverage and high-tissue distribution provide potency for a wide variety of community-acquired infections,” according to background information in the article. Although fluoroquinolones are generally well tolerated, they have been associated with a wide array of adverse events and linked to several forms of ocular toxicity such as corneal perforations, optic neuropathy, and retinal hemorrhages. “Despite numerous case reports of ocular toxicity, a pharmacoepidemiological study of their ocular safety, particularly retinal detachment, has not been performed,” the authors write. “Retinal detachment is a serious medical emergency that may lead to irreversible vision loss.”
Mahyar Etminan, PharmD, MSc (epi), of the Child and Family Research Institute of British Columbia, Vancouver, Canada, and colleagues conducted a study to examine the association between oral fluoroquinolone use and the risk of retinal detachment. The study consisted of a group of patients in British Columbia who had visited an ophthalmologist between January 2000 and December 2007. Retinal detachment cases were defined as a procedure code for retinal repair surgery within 14 days of a physician service code. Ten controls were selected for each case.
The overall cohort included 989,591 patients; within this group, 4,384 cases of retinal detachment and 43,840 corresponding controls were identified for analysis. Cases were more likely to be male and were more likely to have myopia (near-sightedness), diabetes, or have received cataract surgery. The researchers found that retinal detachment was associated with a higher likelihood of current use of fluoroquinolones (3.3 percent of cases vs. 0.6 percent of controls). For current users, the average number of days from the first fluoroquinolone prescription to the first event of a retinal detachment was 4.8 days. No risk was observed among recent users (0.3 percent of cases vs. 0.2 percent of controls) or past users (6.6 percent of cases vs. 6.1 percent of controls). The authors note that the absolute increase in the risk for this condition was small (number needed to harm = 2,500 for any use of fluoroquinolones).
No risk was observed among current users of ß-lactam antibiotics or short-acting ß-agonists.
“This is the first study, to our knowledge, demonstrating that oral fluoroquinolones are associated with an increase in the risk of a retinal detachment. Current users of oral fluoroquinolones were nearly 5 times more likely to be diagnosed with retinal detachment than nonusers,” the researchers write, although because retinal detachment is rare among unexposed patients, the absolute risk increase is low.
The authors add that the risk of retinal detachment in their study was only elevated among current users but not among recent or past users, indicating an acute adverse event. They note that the exact mechanism of retinal detachment with fluoroquinolones is unknown.
“Future pharmacoepidemiological studies should be conducted to confirm or refute these findings,” the researchers conclude.
Reference: JAMA. 2012;307:1414-1419.